TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Clinical Research Advantage, Inc.		09/18/2012	CORPORATION: ARIZONA

RECEIVING PARTY DATA

Name:	TCF National Bank
Street Address:	800 Burr Ridge Parkway
City:	Burr Ridge
State/Country:	ILLINOIS
Postal Code:	60527
Entity Type:	National Banking Association: UNITED STATES

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Registration Number:	3637316	CLINICAL RESEARCH ADVANTAGE
Registration Number:	3597155	CLINICAL RESEARCH ADVANTAGE

CORRESPONDENCE DATA

Fax Number: 3122585700

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Phone: 312-258-5724

Email: cbollinger@schiffhardin.com

Correspondent Name: Chris L. Bollinger
Address Line 1: P.O. Box 06079
Address Line 2: Schiff Hardin LLp

Address Line 4: Chicago, ILLINOIS 60606-0079

ATTORNEY DOCKET NUMBER:	41357-0003
NAME OF SUBMITTER:	Chris L. Bollinger
Signature:	/Chris L. Bollinger/

900234800 REEL: 004870 FRAME: 0555

3637316

ICH \$65.00

Date:	10/01/2012
Total Attachments: 5 source=10-1 - CRA TM Security#page1.tif source=10-1 - CRA TM Security#page2.tif source=10-1 - CRA TM Security#page3.tif source=10-1 - CRA TM Security#page4.tif source=10-1 - CRA TM Security#page5.tif	

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT (this "<u>Agreement</u>"), dated as of September 18, 2012, is made by Clinical Research Advantage, Inc., an Arizona corporation (the "<u>Company</u>"), in favor of TCF National Bank (the "<u>Lender</u>").

RECITALS

WHEREAS, the Company, CRA Intermediate Holdings, Inc., a Delaware corporation ("<u>CRA Holdings</u>"), Innova Holdings, Inc., a Delaware corporation ("<u>RR Holdings</u>"), Radiant Research, Inc., a Delaware corporation ("<u>RR</u>"; the Company, CRA Holdings, RR Holdings and RR are referred to herein, collectively, as the "<u>Obligors</u>" and, individually, as an "<u>Obligor</u>"), and the Lender are parties to a Credit Agreement dated as of September 18, 2012 (as amended, restated, supplemented or otherwise modified from time to time, the "<u>Credit Agreement</u>"), pursuant to which the Lender has agreed to make certain loans to the Company and RR;

WHEREAS, the Obligors and the Lender are parties to a Security Agreement dated as of September 18, 2012 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"); and

WHEREAS, pursuant to the terms of the Credit Agreement and the Security Agreement, the Company has granted to the Lender a security interest in substantially all the assets of the Company, including, with the exception of the Excluded Property, all right, title and interest of the Company in, to and under all now existing and hereafter arising service marks, trademarks, trademark or service mark registrations, trademark or service mark applications and trade names, all renewals thereof, all income, royalties, damages and payments now and hereafter due and/or payable with respect thereto arising in favor of the Company, and the goodwill of the Company's business connected with and symbolized thereby, to secure the payment and performance in full of all amounts owing by the Company under the Credit Agreement and the other Financing Agreements (as defined in the Credit Agreement);

NOW, THEREFORE, in consideration of the mutual agreements set forth herein and in the Credit Agreement, the Company hereby grants to the Lender a security interest in all of the Company's right, title and interest in and to the following, whether now existing and hereafter arising:

- (1) each trademark and trademark application, including, without limitation, each trademark and trademark application referred to in <u>Schedule 1</u> annexed hereto, and all renewals thereof, together with the goodwill of the Company's business connected with and symbolized thereby;
- (2) all license agreements with any other Person or Persons with respect to any service marks, trademarks, trademark or service mark registrations, trademark or service mark applications and trade names, whether the Company is a licensor or licensee under any such license agreements, and, subject to the terms of such licenses, the right to prepare for sale, sell and advertise for sale, all inventory now

- or hereafter owned by the Company and now or hereafter covered by such licenses; and
- (3) all products and proceeds of the foregoing, including, without limitation, all income, royalties, damages and payments now and hereafter due and/or payable with respect thereto arising in favor of the Company (items 1 through 3 being herein collectively referred to as the "Trademark Collateral");

<u>provided</u>, <u>however</u>, that there shall be excluded from the foregoing grant of security interest all Excluded Property (as such term is defined in the Security Agreement).

This security interest is granted in conjunction with the security interests granted to the Lender pursuant to the Credit Agreement and the Security Agreement and is subject to limitations set forth therein. In the event of any conflict between any provision of this Agreement and any provision of the Credit Agreement or the Security Agreement, the Credit Agreement or the Security Agreement, respectively, will govern. Each of the Company and the Lender hereby acknowledges and affirms that the rights and remedies of the Lender with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Credit Agreement, the Credit Agreement and the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

[signature page follows]

IN WITNESS WHEREOF, the Company has caused this Trademark Security Agreement to be duly executed by its duly authorized officer thereunto as of the date first set forth above.

	CLINICAL RESEARCH ADVANTAGE, IN		
	Name:	Mark Hanley	
	Title:	Chief Executive Officer	
Acknowledged and agreed to: TCF NATIONAL BANK			
By:			
Name:			
Title:			

IN WITNESS WHEREOF, the Company has caused this Trademark Security Agreement to be duly executed by its duly authorized officer thereunto as of the date first set forth above.

CLINICAL RESEARCH ADVANTAGE, INC.

	By:Name:Title:
Acknowledged and agreed to: TCF NATIONAL BANK	
By: Thomas Acharle Name: Thomas G. Karle Title: SVP	

SCHEDULE 1

to

TRADEMARK SECURITY AGREEMENT

Mark	Issue No.	Issue Date	Serial No.	Filed	Owner
CLINICAL RESEARCH	3637316	6-16-2009	77247167	8-03-2007	Clinical Research
ADVANTAGE					Advantage Corp.
CLINICAL RESEARCH	3597155	3-31-2009	77247158	8-03-2007	Clinical Research
ADVANTAGE					Advantage Corp.

CH2\11810952.4

TRADEMARK REEL: 004870 FRAME: 0561

RECORDED: 10/01/2012